Immortalized car-t cells genetically modified to elminate t-cell receptor and beta 2-microglobulin expression
US-2019175651-A1 · Jun 13, 2019 · US
Antigen binding regions against fibronectin type III domains and methods of using the same
US12269870B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12269870-B2 |
| Application number | US-202117493032-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 4, 2021 |
| Priority date | Jul 17, 2017 |
| Publication date | Apr 8, 2025 |
| Grant date | Apr 8, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Fibronectin type III (FN3) domain antibodies, polynucleotides capable of encoding the FN3 domain antibodies or antigen-binding fragments, cells expressing FN3 domain antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled FN3 domain antibodies or antigen-binding fragments may be used to engineer FN3 domain-targeting chimeric antigen receptors (CARs). Methods of making the FN3 domain antibodies, CARs, and engineered immune cells, and methods of using the engineered immune cells are applicable to treat diseases including cancer.
First claim
Opening claim text (preview).
We claim: 1. An isolated polynucleotide encoding a chimeric antigen receptor (CAR) comprising: (a) an extracellular domain comprising an scFv comprising the amino acid sequence of SEQ ID NOs: 72 or 73, wherein the extracellular domain specifically binds to a non-randomized region of an FN3 domain; (b) a transmembrane domain comprising the amino acid sequence of SEQ ID NO: 25; and (c) an intracellular signaling domain comprising a co-stimulatory domain comprising the amino acid sequence of SEQ ID NO: 26, and a primary signaling domain comprising the amino acid sequence of SEQ ID NO: 27, wherein the CAR optionally further comprises a hinge region comprising the amino acid sequence of SEQ ID NO: 24 connecting the extracellular domain and the transmembrane domain. 2. A vector comprising the polynucleotide of claim 1 . 3. A host cell comprising the vector of claim 2 . 4. A host cell comprising the polynucleotide of claim 1 .
Assignees
Inventors
Classifications
fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies · CPC title
Complementarity determining region [CDR] · CPC title
containing a transmembrane segment · CPC title
Single chain antibody (scFv) · CPC title
containing a signal sequence · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12269870B2 cover?
- Fibronectin type III (FN3) domain antibodies, polynucleotides capable of encoding the FN3 domain antibodies or antigen-binding fragments, cells expressing FN3 domain antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled FN3 domain antibodies or antigen-binding fragments may be used to engineer FN3 domain-targeting chimeric antigen receptors (CARs). Method…
- Who is the assignee on this patent?
- Janssen Biotech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/18. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).